Defects in mitochondrial gene expression can cause a myriad of mitochondrial disorders, including mitochondrial encephalopathy, lactic acidosis and stroke-like episodes (MELAS) syndrome, Kearns-Sayre syndrome, and Leber hereditary optic neuropathy. These diseases have a large impact in the population since, when considered as a class, they are estimated to have a prevalence of at least 1 in 5000. Furthermore, a progressive decay in mitochondrial function is associated with human aging and mitochondrial deficiencies are thought to contribute to the onset of age-related diseases. Clear associations exist between deficiencies in mitochondrial function and neurodegenerative diseases such as Alzheimer's and Parkinson's disease, as well as diabetes and cancer. There is extensive evidence linking mitochondrial deficiencies to human pathology, and in particular of the central role that defects in mitochondrial gene expression play in pathogenesis. A crucial requirement for mitochondrial gene expression is proper ribosome biogenesis. This process, which is not well understood, involves several posttranscriptional RNA modifications that are thought to be crucial for ribosome assembly. KsgA and Dim1 methyltransferases dimethylate two adjacent adenine residues in a conserved stem-loop in the small subunit of the bacterial and eukaryotic ribosomes, respectively. Both the stem-loop structure and methylation events are conserved in the human 12S mitochondrial rRNA. Mitochondrial transcription factor B1 (TFB1M) is essential for mammalian development and catalyzes the analogous rRNA modification in mitochondria. Methylation by KsgA is related to bacterial aminoglycoside sensitivity and TFB1M activity could similarly be related to the effect of aminoglycoside antibiotics on the mitochondrial ribosome and aminoglycoside-induced hearing loss. Consistently, aminoglycoside sensitivity in humans is often maternally inherited, and methylation activity by TFB1M modulates the effects of a pathogenic mtDNA mutation linked to deafness. Other TFB1M polymorphisms are associated with reduced insulin secretion and increased risk of type II diabetes mellitus, further highlightin the importance of this modification for normal mitochondrial function. Metazoan mitochondria contain a second TFB family member, TFB2M, in addition to TFB1M. TFB2M was discovered along with TFB1M as a putative mitochondrial transcription factor that associates with the mitochondrial RNA polymerase and promotes initiation of mitochondrial transcription. It is now accepted that TFB2M is essential for the initiation of transcription in mitochondria, yet surprisingly, neither TFB1M nor TFB2M display similarity to any known transcription factor, raising the question of why a protein with a predicted methyltransferase fold plays a central role in transcription initiation. This question remains unanswered, since the mechanism by which TFB2M promotes initiation is not yet known. Both TFB1M and TFB2M are predicted to adopt methyltransferase folds, yet their atomic structures remain unknown. Key structural differences must exist between them that explain their evident functional divergence. The goal of this proposal is to provide a more complete understanding of how TFB proteins influence disease pathogenesis by elucidating the roles that they play in mitochondrial gene expression.

Public Health Relevance

Roughly one out of every 4000 children born in the United States will develop a mitochondrial disease before the age of 10. The mortality rate is roughly that of cancer, and there is no cure or proven treatment. Mitochondrial dysfunction is also involved in aging and age-related diseases, neurodegenerative disorders, diabetes, and cancer. Much work is needed to understand these processes and ultimately, develop improved treatments for these devastating disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Individual Predoctoral NRSA for M.D./Ph.D. Fellowships (ADAMHA) (F30)
Project #
1F30ES022930-01A1
Application #
8527219
Study Section
Special Emphasis Panel (ZRG1-F04-W (20))
Program Officer
Humble, Michael C
Project Start
2013-06-01
Project End
2015-05-31
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
1
Fiscal Year
2013
Total Cost
$47,232
Indirect Cost
Name
State University New York Stony Brook
Department
Pharmacology
Type
Schools of Medicine
DUNS #
804878247
City
Stony Brook
State
NY
Country
United States
Zip Code
11794
Yakubovskaya, Elena; Guja, Kip E; Eng, Edward T et al. (2014) Organization of the human mitochondrial transcription initiation complex. Nucleic Acids Res 42:4100-12
Venkataraman, Krithika; Guja, Kip E; Garcia-Diaz, Miguel et al. (2014) Non-stop mRNA decay: a special attribute of trans-translation mediated ribosome rescue. Front Microbiol 5:93
Yang, Meng; Guja, Kip E; Thomas, Suzanne T et al. (2014) A distinct MaoC-like enoyl-CoA hydratase architecture mediates cholesterol catabolism in Mycobacterium tuberculosis. ACS Chem Biol 9:2632-45
Guja, Kip E; Venkataraman, Krithika; Yakubovskaya, Elena et al. (2013) Structural basis for S-adenosylmethionine binding and methyltransferase activity by mitochondrial transcription factor B1. Nucleic Acids Res 41:7947-59
Jacewicz, Agata; Trzemecka, Anna; Guja, Kip E et al. (2013) A remote palm domain residue of RB69 DNA polymerase is critical for enzyme activity and influences the conformation of the active site. PLoS One 8:e76700